Somesh Nigam
Research Subjects
Somesh Nigam has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
B Vicidomina
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publications- Erika Alejandra Zúñiga San Lucas
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publications - Miao Liu
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publications T. Bergeron
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publicationsY. Zhang
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publications- Yunqing Zhang
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publications
Latest Publications
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S308
OP4 Prioritization of ADT Notifications Improves Efficiency of New Blue Cross and Blue Shield of Louisiana Care Management Referral Process
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S308
OP4 Prioritization of ADT Notifications Improves Efficiency of New Blue Cross and Blue Shield of Louisiana Care Management Referral Process
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S491
HSD64 The Influence of COVID-19 on Telemedicine Services Among Blue Cross and Blue Shield of Louisiana Members with Diabetes
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S491
HSD64 The Influence of COVID-19 on Telemedicine Services Among Blue Cross and Blue Shield of Louisiana Members with Diabetes
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S559
PCR98 The Continued Success of Value-Based Insurance Design (VBID): Blue Cross and Blue Shield of Louisiana's $0 Drug Co-Pay Program
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S559
PCR98 The Continued Success of Value-Based Insurance Design (VBID): Blue Cross and Blue Shield of Louisiana's $0 Drug Co-Pay Program
- Open Access
- 13 February 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (6) , 557-565
Evaluation of four disease management programs: evidence from blue cross blue shield of Louisiana
Aims: Chronic diseases impose a substantial healthcare burden. This study sought to evaluate the clinical and economic impact of new disease management (DM) programs, targeting 4 major chronic disease groups: diabetes, coronary heart disease (CHD)/hypertension (HTN), asthma/chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF)/chronic kidney disease (CKD). Materials and Methods: Between March 1, 2015, and February 28, 2018, members with Blue Cross Blue Shield of Louisiana insurance were contacted and enrolled in a DM program if they were aged 18 years through 64 years, eligible for a DM program, and had not been previously enrolled in a DM program. Active enrollees of a DM program (‘IN’ group) were compared to members who were not yet enrolled (‘OUT’ group). Average per member per month (PMPM) costs were aggregated annually to document any descriptive trends. Multivariable model estimates were used to compare PMPM costs for all IN subjects and all OUT subjects. Total medical savings were evaluated for the following time intervals: 1-12 months, 13-24 months, and 25-36 months. Results: For all 4 DM programs, average costs PMPM trended upward over time for the OUT cohort, while they remained relatively stable for the IN cohort. Some evidence also showed that DM programs improved clinical outcomes, such as hemoglobin A1c values. A difference in difference analysis showed PMPM savings for all 4 programs combined of $31.61, $50.45, and $53.72 after 1, 2, and 3 years, respectively. Multivariable modeling results showed total savings after 3 years of $14,460,174 for all DM programs combined. Limitations: Although multivariable models adjusted for several clinical, demographic, and economic characteristics; it is possible that some important confounders were missing due to lack of data. Conclusions: DM programs implemented to control diabetes, CHD/HTN, CHF/CKD, and asthma/COPD are cost-effective and show some evidence of improved clinical outcomes.
- 13 February 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (6) , 557-565
Open AccessEvaluation of four disease management programs: evidence from blue cross blue shield of Louisiana
Aims: Chronic diseases impose a substantial healthcare burden. This study sought to evaluate the clinical and economic impact of new disease management (DM) programs, targeting 4 major chronic disease groups: diabetes, coronary heart disease (CHD)/hypertension (HTN), asthma/chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF)/chronic kidney disease (CKD). Materials and Methods: Between March 1, 2015, and February 28, 2018, members with Blue Cross Blue Shield of Louisiana insurance were contacted and enrolled in a DM program if they were aged 18 years through 64 years, eligible for a DM program, and had not been previously enrolled in a DM program. Active enrollees of a DM program (‘IN’ group) were compared to members who were not yet enrolled (‘OUT’ group). Average per member per month (PMPM) costs were aggregated annually to document any descriptive trends. Multivariable model estimates were used to compare PMPM costs for all IN subjects and all OUT subjects. Total medical savings were evaluated for the following time intervals: 1-12 months, 13-24 months, and 25-36 months. Results: For all 4 DM programs, average costs PMPM trended upward over time for the OUT cohort, while they remained relatively stable for the IN cohort. Some evidence also showed that DM programs improved clinical outcomes, such as hemoglobin A1c values. A difference in difference analysis showed PMPM savings for all 4 programs combined of $31.61, $50.45, and $53.72 after 1, 2, and 3 years, respectively. Multivariable modeling results showed total savings after 3 years of $14,460,174 for all DM programs combined. Limitations: Although multivariable models adjusted for several clinical, demographic, and economic characteristics; it is possible that some important confounders were missing due to lack of data. Conclusions: DM programs implemented to control diabetes, CHD/HTN, CHF/CKD, and asthma/COPD are cost-effective and show some evidence of improved clinical outcomes.
- Open Access
- 31 January 2020
- Published by Korean Stroke Society in Journal of Stroke
- Vol. 22 (1) , 87-98
Association between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes
Background and Purpose The association between hemoglobin A1c (HbA1c) and stroke risk along with its subtypes is rarely reported. We aimed to investigate the association between HbA1c and the risk of incident stroke in patients with type 2 diabetes based on real world data from three healthcare systems.Methods We performed a retrospective cohort study of 27,113 African Americans and 40,431 whites with type 2 diabetes. Demographic, anthropometric, laboratory, and medication information were abstracted from the National Patient-Centered Clinical Research Network common data model. Incident stroke events including both ischemic and hemorrhagic stroke were defined.Results During a mean follow-up period of 3.79±1.68 years, 7,735 patients developed stroke (6,862 ischemic and 873 hemorrhagic). Multivariable-adjusted hazard ratios across levels of HbA1c at baseline (<6.0%, 6.0% to 6.9% [reference group], 7.0% to 7.9%, 8.0% to 8.9%, 9.0% to 9.9%, and ≥10%) were 1.07, 1.00, 1.13, 1.23, 1.27, and 1.37 (Ptrend <0.001) for total stroke, 1.02, 1.00, 1.13, 1.20, 1.24, and 1.35 (Ptrend <0.001) for ischemic stroke, and 1.40, 1.00, 1.14, 1.47, 1.47, and 1.51 (Ptrend=0.002) for hemorrhagic stroke. When we used an updated mean value of HbA1c, the U-shaped association of HbA1c with stroke risk did not change. This U-shaped association was consistent among patients of different subgroups. The U-shaped association was more pronounced among patients taking antidiabetic, lipid-lowering, and antihypertensive medications compared with those without these medications.Conclusions These data suggest that diabetes management may have to be individualized according to the guideline recommendations rather than intensively attempting to lower HbA1c.
- 31 January 2020
- Published by Korean Stroke Society in Journal of Stroke
- Vol. 22 (1) , 87-98
Open AccessAssociation between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes
Background and Purpose The association between hemoglobin A1c (HbA1c) and stroke risk along with its subtypes is rarely reported. We aimed to investigate the association between HbA1c and the risk of incident stroke in patients with type 2 diabetes based on real world data from three healthcare systems.Methods We performed a retrospective cohort study of 27,113 African Americans and 40,431 whites with type 2 diabetes. Demographic, anthropometric, laboratory, and medication information were abstracted from the National Patient-Centered Clinical Research Network common data model. Incident stroke events including both ischemic and hemorrhagic stroke were defined.Results During a mean follow-up period of 3.79±1.68 years, 7,735 patients developed stroke (6,862 ischemic and 873 hemorrhagic). Multivariable-adjusted hazard ratios across levels of HbA1c at baseline (<6.0%, 6.0% to 6.9% [reference group], 7.0% to 7.9%, 8.0% to 8.9%, 9.0% to 9.9%, and ≥10%) were 1.07, 1.00, 1.13, 1.23, 1.27, and 1.37 (Ptrend <0.001) for total stroke, 1.02, 1.00, 1.13, 1.20, 1.24, and 1.35 (Ptrend <0.001) for ischemic stroke, and 1.40, 1.00, 1.14, 1.47, 1.47, and 1.51 (Ptrend=0.002) for hemorrhagic stroke. When we used an updated mean value of HbA1c, the U-shaped association of HbA1c with stroke risk did not change. This U-shaped association was consistent among patients of different subgroups. The U-shaped association was more pronounced among patients taking antidiabetic, lipid-lowering, and antihypertensive medications compared with those without these medications.Conclusions These data suggest that diabetes management may have to be individualized according to the guideline recommendations rather than intensively attempting to lower HbA1c.